nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—MYT1—spinal cord—meningioma	0.00754	0.0238	CbGeAlD
Dasatinib—EPHB2—brainstem—meningioma	0.00664	0.021	CbGeAlD
Dasatinib—STAT5B—brainstem—meningioma	0.00602	0.019	CbGeAlD
Dasatinib—MYT1—cerebellum—meningioma	0.00598	0.0189	CbGeAlD
Dasatinib—PKMYT1—medulla oblongata—meningioma	0.00485	0.0153	CbGeAlD
Dasatinib—MYT1—brain—meningioma	0.00485	0.0153	CbGeAlD
Dasatinib—EPHB3—brainstem—meningioma	0.00438	0.0138	CbGeAlD
Dasatinib—STK35—brainstem—meningioma	0.0041	0.013	CbGeAlD
Dasatinib—EPHB1—cerebellum—meningioma	0.00399	0.0126	CbGeAlD
Dasatinib—EPHA4—brainstem—meningioma	0.00366	0.0116	CbGeAlD
Dasatinib—EPHA5—medulla oblongata—meningioma	0.00343	0.0109	CbGeAlD
Dasatinib—PKMYT1—cerebellum—meningioma	0.00343	0.0108	CbGeAlD
Dasatinib—MAPK14—brainstem—meningioma	0.00337	0.0107	CbGeAlD
Dasatinib—BTK—medulla oblongata—meningioma	0.00335	0.0106	CbGeAlD
Dasatinib—EPHB1—brain—meningioma	0.00324	0.0102	CbGeAlD
Dasatinib—EPHA8—cerebellum—meningioma	0.00314	0.00992	CbGeAlD
Dasatinib—FYN—brainstem—meningioma	0.00313	0.00989	CbGeAlD
Dasatinib—TESK1—medulla oblongata—meningioma	0.0031	0.0098	CbGeAlD
Dasatinib—EPHA5—spinal cord—meningioma	0.00306	0.00968	CbGeAlD
Dasatinib—STK36—medulla oblongata—meningioma	0.00305	0.00965	CbGeAlD
Dasatinib—BTK—spinal cord—meningioma	0.00299	0.00943	CbGeAlD
Dasatinib—STAT5B—cerebellum—meningioma	0.00297	0.00938	CbGeAlD
Dasatinib—SIK2—brain—meningioma	0.00286	0.00904	CbGeAlD
Dasatinib—CSK—medulla oblongata—meningioma	0.00284	0.00898	CbGeAlD
Dasatinib—HCK—medulla oblongata—meningioma	0.00281	0.00887	CbGeAlD
Dasatinib—PKMYT1—brain—meningioma	0.00279	0.00881	CbGeAlD
Dasatinib—TESK1—spinal cord—meningioma	0.00277	0.00874	CbGeAlD
Dasatinib—EPHB3—spinal cord—meningioma	0.00272	0.0086	CbGeAlD
Dasatinib—SIK3—cerebellum—meningioma	0.00267	0.00843	CbGeAlD
Dasatinib—EPHB2—brain—meningioma	0.00266	0.0084	CbGeAlD
Dasatinib—RIPK2—medulla oblongata—meningioma	0.00264	0.00834	CbGeAlD
Dasatinib—LIMK2—spinal cord—meningioma	0.00263	0.00832	CbGeAlD
Dasatinib—SRMS—brain—meningioma	0.0026	0.00822	CbGeAlD
Dasatinib—SIK1—medulla oblongata—meningioma	0.00258	0.00814	CbGeAlD
Dasatinib—EPHA4—medulla oblongata—meningioma	0.00255	0.00806	CbGeAlD
Dasatinib—EPHA8—brain—meningioma	0.00255	0.00806	CbGeAlD
Dasatinib—CSK—spinal cord—meningioma	0.00253	0.00801	CbGeAlD
Dasatinib—HCK—spinal cord—meningioma	0.0025	0.00791	CbGeAlD
Dasatinib—MAP2K5—brainstem—meningioma	0.0025	0.0079	CbGeAlD
Dasatinib—ZAK—cerebellum—meningioma	0.00248	0.00784	CbGeAlD
Dasatinib—EPHA5—cerebellum—meningioma	0.00243	0.00767	CbGeAlD
Dasatinib—STAT5B—brain—meningioma	0.00241	0.00762	CbGeAlD
Dasatinib—BMPR1B—cerebellum—meningioma	0.00238	0.00752	CbGeAlD
Dasatinib—RIPK2—spinal cord—meningioma	0.00235	0.00743	CbGeAlD
Dasatinib—TNK2—cerebellum—meningioma	0.00233	0.00737	CbGeAlD
Dasatinib—SIK1—spinal cord—meningioma	0.0023	0.00726	CbGeAlD
Dasatinib—ERBB3—spinal cord—meningioma	0.00225	0.00711	CbGeAlD
Dasatinib—EPHB4—medulla oblongata—meningioma	0.00223	0.00704	CbGeAlD
Dasatinib—EPHA3—brain—meningioma	0.00223	0.00704	CbGeAlD
Dasatinib—KIT—brainstem—meningioma	0.00222	0.007	CbGeAlD
Dasatinib—JAK2—medulla oblongata—meningioma	0.00221	0.00699	CbGeAlD
Dasatinib—TESK1—cerebellum—meningioma	0.00219	0.00693	CbGeAlD
Dasatinib—FYN—medulla oblongata—meningioma	0.00218	0.0069	CbGeAlD
Dasatinib—SIK3—brain—meningioma	0.00217	0.00685	CbGeAlD
Dasatinib—EPHB3—cerebellum—meningioma	0.00216	0.00682	CbGeAlD
Dasatinib—STK36—cerebellum—meningioma	0.00216	0.00682	CbGeAlD
Dasatinib—MAP4K5—medulla oblongata—meningioma	0.00213	0.00674	CbGeAlD
Dasatinib—MAP3K3—medulla oblongata—meningioma	0.00213	0.00674	CbGeAlD
Dasatinib—MAPK14—spinal cord—meningioma	0.0021	0.00663	CbGeAlD
Dasatinib—LIMK2—cerebellum—meningioma	0.00209	0.00659	CbGeAlD
Dasatinib—EPHB6—medulla oblongata—meningioma	0.00204	0.00644	CbGeAlD
Dasatinib—STK35—cerebellum—meningioma	0.00202	0.00639	CbGeAlD
Dasatinib—ZAK—brain—meningioma	0.00202	0.00637	CbGeAlD
Dasatinib—CSK—cerebellum—meningioma	0.00201	0.00635	CbGeAlD
Dasatinib—EPHB4—spinal cord—meningioma	0.00199	0.00628	CbGeAlD
Dasatinib—JAK2—spinal cord—meningioma	0.00197	0.00624	CbGeAlD
Dasatinib—EPHA5—brain—meningioma	0.00197	0.00623	CbGeAlD
Dasatinib—ABL2—cerebellum—meningioma	0.00197	0.00623	CbGeAlD
Dasatinib—YES1—medulla oblongata—meningioma	0.00197	0.00623	CbGeAlD
Dasatinib—LYN—brain—meningioma	0.00196	0.0062	CbGeAlD
Dasatinib—FYN—spinal cord—meningioma	0.00195	0.00615	CbGeAlD
Dasatinib—BMPR1B—brain—meningioma	0.00193	0.00611	CbGeAlD
Dasatinib—MAP3K19—brain—meningioma	0.00193	0.00611	CbGeAlD
Dasatinib—ABL1—brainstem—meningioma	0.00193	0.00609	CbGeAlD
Dasatinib—BTK—brain—meningioma	0.00192	0.00608	CbGeAlD
Dasatinib—MAP4K5—spinal cord—meningioma	0.0019	0.00601	CbGeAlD
Dasatinib—MAP3K3—spinal cord—meningioma	0.0019	0.00601	CbGeAlD
Dasatinib—TNK2—brain—meningioma	0.00189	0.00599	CbGeAlD
Dasatinib—RIPK2—cerebellum—meningioma	0.00187	0.00589	CbGeAlD
Dasatinib—SIK1—cerebellum—meningioma	0.00182	0.00576	CbGeAlD
Dasatinib—EPHB6—spinal cord—meningioma	0.00182	0.00574	CbGeAlD
Dasatinib—EPHA4—cerebellum—meningioma	0.0018	0.0057	CbGeAlD
Dasatinib—ERBB3—cerebellum—meningioma	0.00179	0.00564	CbGeAlD
Dasatinib—TESK1—brain—meningioma	0.00178	0.00563	CbGeAlD
Dasatinib—MAP3K2—cerebellum—meningioma	0.00177	0.00559	CbGeAlD
Dasatinib—YES1—spinal cord—meningioma	0.00176	0.00555	CbGeAlD
Dasatinib—EPHB3—brain—meningioma	0.00175	0.00554	CbGeAlD
Dasatinib—STK36—brain—meningioma	0.00175	0.00554	CbGeAlD
Dasatinib—MAP2K5—medulla oblongata—meningioma	0.00174	0.00551	CbGeAlD
Dasatinib—PDGFRA—spinal cord—meningioma	0.00172	0.00545	CbGeAlD
Dasatinib—CSF1R—medulla oblongata—meningioma	0.0017	0.00538	CbGeAlD
Dasatinib—LIMK2—brain—meningioma	0.0017	0.00536	CbGeAlD
Dasatinib—SRC—spinal cord—meningioma	0.00169	0.00534	CbGeAlD
Dasatinib—MAPK14—cerebellum—meningioma	0.00166	0.00525	CbGeAlD
Dasatinib—STK35—brain—meningioma	0.00164	0.00519	CbGeAlD
Dasatinib—CSK—brain—meningioma	0.00163	0.00516	CbGeAlD
Dasatinib—HCK—brain—meningioma	0.00161	0.00509	CbGeAlD
Dasatinib—ABL2—brain—meningioma	0.0016	0.00506	CbGeAlD
Dasatinib—EPHB4—cerebellum—meningioma	0.00158	0.00498	CbGeAlD
Dasatinib—JAK2—cerebellum—meningioma	0.00156	0.00494	CbGeAlD
Dasatinib—MAP2K5—spinal cord—meningioma	0.00155	0.00491	CbGeAlD
Dasatinib—KIT—medulla oblongata—meningioma	0.00154	0.00488	CbGeAlD
Dasatinib—FYN—cerebellum—meningioma	0.00154	0.00488	CbGeAlD
Dasatinib—CSF1R—spinal cord—meningioma	0.00152	0.00479	CbGeAlD
Dasatinib—RIPK2—brain—meningioma	0.00151	0.00479	CbGeAlD
Dasatinib—PDGFRB—medulla oblongata—meningioma	0.00151	0.00477	CbGeAlD
Dasatinib—MAP4K5—cerebellum—meningioma	0.00151	0.00477	CbGeAlD
Dasatinib—MAP3K3—cerebellum—meningioma	0.00151	0.00477	CbGeAlD
Dasatinib—SIK1—brain—meningioma	0.00148	0.00467	CbGeAlD
Dasatinib—EPHA4—brain—meningioma	0.00146	0.00463	CbGeAlD
Dasatinib—ERBB3—brain—meningioma	0.00145	0.00458	CbGeAlD
Dasatinib—EPHB6—cerebellum—meningioma	0.00144	0.00455	CbGeAlD
Dasatinib—MAP3K2—brain—meningioma	0.00144	0.00454	CbGeAlD
Dasatinib—YES1—cerebellum—meningioma	0.00139	0.0044	CbGeAlD
Dasatinib—KIT—spinal cord—meningioma	0.00138	0.00435	CbGeAlD
Dasatinib—PDGFRA—cerebellum—meningioma	0.00137	0.00432	CbGeAlD
Dasatinib—MAPK14—brain—meningioma	0.00135	0.00427	CbGeAlD
Dasatinib—PDGFRB—spinal cord—meningioma	0.00135	0.00425	CbGeAlD
Dasatinib—ABL1—medulla oblongata—meningioma	0.00134	0.00425	CbGeAlD
Dasatinib—FGR—brain—meningioma	0.00134	0.00425	CbGeAlD
Dasatinib—SRC—cerebellum—meningioma	0.00134	0.00423	CbGeAlD
Dasatinib—FMO3—brain—meningioma	0.0013	0.0041	CbGeAlD
Dasatinib—EPHB4—brain—meningioma	0.00128	0.00404	CbGeAlD
Dasatinib—JAK2—brain—meningioma	0.00127	0.00402	CbGeAlD
Dasatinib—EPHA2—brain—meningioma	0.00126	0.00397	CbGeAlD
Dasatinib—FYN—brain—meningioma	0.00125	0.00396	CbGeAlD
Dasatinib—MAP2K5—cerebellum—meningioma	0.00123	0.0039	CbGeAlD
Dasatinib—MAP3K3—brain—meningioma	0.00123	0.00387	CbGeAlD
Dasatinib—MAP4K5—brain—meningioma	0.00123	0.00387	CbGeAlD
Dasatinib—CSF1R—cerebellum—meningioma	0.0012	0.0038	CbGeAlD
Dasatinib—ABL1—spinal cord—meningioma	0.0012	0.00379	CbGeAlD
Dasatinib—EPHB6—brain—meningioma	0.00117	0.0037	CbGeAlD
Dasatinib—YES1—brain—meningioma	0.00113	0.00358	CbGeAlD
Dasatinib—PDGFRA—brain—meningioma	0.00111	0.00351	CbGeAlD
Dasatinib—KIT—cerebellum—meningioma	0.00109	0.00345	CbGeAlD
Dasatinib—SRC—brain—meningioma	0.00109	0.00344	CbGeAlD
Dasatinib—PDGFRB—cerebellum—meningioma	0.00107	0.00337	CbGeAlD
Dasatinib—MAP2K5—brain—meningioma	0.001	0.00316	CbGeAlD
Dasatinib—CSF1R—brain—meningioma	0.000977	0.00309	CbGeAlD
Dasatinib—ABL1—cerebellum—meningioma	0.000951	0.003	CbGeAlD
Dasatinib—KIT—brain—meningioma	0.000887	0.0028	CbGeAlD
Dasatinib—PDGFRB—brain—meningioma	0.000867	0.00274	CbGeAlD
Dasatinib—ABCG2—medulla oblongata—meningioma	0.000848	0.00268	CbGeAlD
Dasatinib—CYP1B1—cerebellum—meningioma	0.000805	0.00254	CbGeAlD
Dasatinib—ABL1—brain—meningioma	0.000772	0.00244	CbGeAlD
Dasatinib—ABCG2—spinal cord—meningioma	0.000756	0.00239	CbGeAlD
Dasatinib—CYP1B1—brain—meningioma	0.000654	0.00207	CbGeAlD
Dasatinib—ABCG2—cerebellum—meningioma	0.0006	0.00189	CbGeAlD
Dasatinib—ABCG2—brain—meningioma	0.000487	0.00154	CbGeAlD
Dasatinib—CYP1A1—brain—meningioma	0.000462	0.00146	CbGeAlD
Dasatinib—ABCB1—medulla oblongata—meningioma	0.000418	0.00132	CbGeAlD
Dasatinib—ABCB1—spinal cord—meningioma	0.000373	0.00118	CbGeAlD
Dasatinib—ABCB1—cerebellum—meningioma	0.000296	0.000934	CbGeAlD
Dasatinib—ABCB1—brain—meningioma	0.00024	0.000759	CbGeAlD
Dasatinib—JAK2—Immune System—PDGFB—meningioma	5.52e-05	8.08e-05	CbGpPWpGaD
Dasatinib—SRC—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	5.52e-05	8.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—PTEN—meningioma	5.49e-05	8.03e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by NGF—AKT1—meningioma	5.48e-05	8.01e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—PTEN—meningioma	5.48e-05	8.01e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—TSHB—meningioma	5.45e-05	7.97e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—PTEN—meningioma	5.42e-05	7.93e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PDGFB—meningioma	5.36e-05	7.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PGR—meningioma	5.35e-05	7.83e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—ERBB2—meningioma	5.35e-05	7.82e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HES1—meningioma	5.34e-05	7.82e-05	CbGpPWpGaD
Dasatinib—BLK—Adaptive Immune System—AKT1—meningioma	5.34e-05	7.82e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—ERBB2—meningioma	5.31e-05	7.76e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—PTEN—meningioma	5.23e-05	7.65e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—HES1—meningioma	5.22e-05	7.64e-05	CbGpPWpGaD
Dasatinib—SRC—Platelet activation, signaling and aggregation—AKT1—meningioma	5.22e-05	7.64e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—PTEN—meningioma	5.15e-05	7.54e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—TSHB—meningioma	5.15e-05	7.53e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PDGFB—meningioma	5.12e-05	7.49e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—meningioma	5.11e-05	7.48e-05	CbGpPWpGaD
Dasatinib—ERBB3—Innate Immune System—AKT1—meningioma	5.1e-05	7.46e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PDGFB—meningioma	5.1e-05	7.46e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALAD—meningioma	5.09e-05	7.45e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—PTEN—meningioma	5.07e-05	7.42e-05	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—AKT1—meningioma	5.07e-05	7.41e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—meningioma	5.06e-05	7.41e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—PTEN—meningioma	5.06e-05	7.41e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HES1—meningioma	5.06e-05	7.4e-05	CbGpPWpGaD
Dasatinib—YES1—Hemostasis—AKT1—meningioma	4.97e-05	7.27e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SMO—meningioma	4.94e-05	7.23e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—ERBB2—meningioma	4.93e-05	7.21e-05	CbGpPWpGaD
Dasatinib—ERBB3—Adaptive Immune System—AKT1—meningioma	4.9e-05	7.16e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—PDGFB—meningioma	4.84e-05	7.08e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—AKT1—meningioma	4.8e-05	7.02e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—PTEN—meningioma	4.76e-05	6.96e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—PTEN—meningioma	4.75e-05	6.94e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—ERBB2—meningioma	4.74e-05	6.93e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PGR—meningioma	4.74e-05	6.93e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—ERBB2—meningioma	4.73e-05	6.92e-05	CbGpPWpGaD
Dasatinib—CSK—Immune System—AKT1—meningioma	4.66e-05	6.82e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HES1—meningioma	4.62e-05	6.76e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PDGFB—meningioma	4.57e-05	6.69e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—PTEN—meningioma	4.56e-05	6.67e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HES1—meningioma	4.56e-05	6.67e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—PTEN—meningioma	4.52e-05	6.62e-05	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—AKT1—meningioma	4.51e-05	6.6e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—ERBB2—meningioma	4.48e-05	6.56e-05	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—AKT1—meningioma	4.48e-05	6.55e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PDGFB—meningioma	4.47e-05	6.53e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HES1—meningioma	4.46e-05	6.53e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—ERBB2—meningioma	4.43e-05	6.48e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HES1—meningioma	4.39e-05	6.43e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—meningioma	4.39e-05	6.42e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—ERBB2—meningioma	4.37e-05	6.4e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—meningioma	4.37e-05	6.39e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PDGFB—meningioma	4.33e-05	6.33e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—meningioma	4.32e-05	6.32e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—AKT1—meningioma	4.3e-05	6.29e-05	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—AKT1—meningioma	4.3e-05	6.29e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PDGFB—meningioma	4.28e-05	6.27e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—AKT1—meningioma	4.28e-05	6.26e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—AKT1—meningioma	4.25e-05	6.21e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HES1—meningioma	4.23e-05	6.19e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—PTEN—meningioma	4.2e-05	6.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HES1—meningioma	4.18e-05	6.11e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—AKT1—meningioma	4.17e-05	6.1e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—meningioma	4.16e-05	6.09e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—ERBB2—meningioma	4.14e-05	6.06e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TSHB—meningioma	4.11e-05	6.01e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	4.11e-05	6.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—meningioma	4.11e-05	6.01e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—ERBB2—meningioma	4.05e-05	5.93e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—ERBB2—meningioma	4.04e-05	5.91e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—PTEN—meningioma	4.04e-05	5.91e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—PTEN—meningioma	4.04e-05	5.9e-05	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—AKT1—meningioma	4.01e-05	5.86e-05	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—AKT1—meningioma	4e-05	5.85e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—ERBB2—meningioma	3.96e-05	5.79e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PDGFB—meningioma	3.95e-05	5.78e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—ERBB2—meningioma	3.94e-05	5.76e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALAD—meningioma	3.93e-05	5.75e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—ERBB2—meningioma	3.91e-05	5.72e-05	CbGpPWpGaD
Dasatinib—BTK—Immune System—AKT1—meningioma	3.9e-05	5.7e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PDGFB—meningioma	3.9e-05	5.7e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—ERBB2—meningioma	3.89e-05	5.7e-05	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—AKT1—meningioma	3.84e-05	5.62e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—PTEN—meningioma	3.82e-05	5.59e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PDGFB—meningioma	3.82e-05	5.58e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—AKT1—meningioma	3.78e-05	5.54e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—PTEN—meningioma	3.78e-05	5.53e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—AKT1—meningioma	3.78e-05	5.53e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—AKT1—meningioma	3.76e-05	5.5e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PDGFB—meningioma	3.76e-05	5.5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—ERBB2—meningioma	3.75e-05	5.49e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—ERBB2—meningioma	3.73e-05	5.46e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—PTEN—meningioma	3.73e-05	5.46e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—AKT1—meningioma	3.72e-05	5.44e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—AKT1—meningioma	3.71e-05	5.42e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—ERBB2—meningioma	3.7e-05	5.42e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—AKT1—meningioma	3.69e-05	5.4e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HES1—meningioma	3.66e-05	5.35e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—AKT1—meningioma	3.65e-05	5.34e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—AKT1—meningioma	3.63e-05	5.32e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PDGFB—meningioma	3.62e-05	5.29e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—meningioma	3.6e-05	5.26e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—ERBB2—meningioma	3.6e-05	5.26e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—AKT1—meningioma	3.58e-05	5.24e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—AKT1—meningioma	3.58e-05	5.23e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PDGFB—meningioma	3.57e-05	5.22e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—meningioma	3.57e-05	5.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—AKT1—meningioma	3.54e-05	5.17e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTEN—meningioma	3.53e-05	5.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—AKT1—meningioma	3.51e-05	5.14e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	3.47e-05	5.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—AKT1—meningioma	3.47e-05	5.08e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PTEN—meningioma	3.46e-05	5.06e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—meningioma	3.46e-05	5.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PTEN—meningioma	3.45e-05	5.04e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—ERBB2—meningioma	3.43e-05	5.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—ERBB2—meningioma	3.42e-05	5e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—AKT1—meningioma	3.41e-05	4.99e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—PTEN—meningioma	3.37e-05	4.93e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—AKT1—meningioma	3.37e-05	4.93e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PTEN—meningioma	3.36e-05	4.91e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—AKT1—meningioma	3.34e-05	4.88e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PTEN—meningioma	3.33e-05	4.87e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—AKT1—meningioma	3.32e-05	4.86e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—PTEN—meningioma	3.32e-05	4.86e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—AKT1—meningioma	3.3e-05	4.83e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—AKT1—meningioma	3.29e-05	4.81e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TSHB—meningioma	3.28e-05	4.8e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—AKT1—meningioma	3.27e-05	4.79e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—ERBB2—meningioma	3.24e-05	4.74e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—AKT1—meningioma	3.24e-05	4.74e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HES1—meningioma	3.24e-05	4.74e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—AKT1—meningioma	3.23e-05	4.73e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—AKT1—meningioma	3.21e-05	4.69e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PTEN—meningioma	3.2e-05	4.68e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—meningioma	3.19e-05	4.66e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTEN—meningioma	3.18e-05	4.65e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—AKT1—meningioma	3.16e-05	4.63e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PTEN—meningioma	3.16e-05	4.62e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—AKT1—meningioma	3.16e-05	4.62e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—meningioma	3.15e-05	4.61e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PDGFB—meningioma	3.13e-05	4.58e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—AKT1—meningioma	3.12e-05	4.57e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTEN—meningioma	3.07e-05	4.49e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—ERBB2—meningioma	3.06e-05	4.48e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—AKT1—meningioma	3.04e-05	4.45e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—AKT1—meningioma	3.01e-05	4.41e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—ERBB2—meningioma	2.99e-05	4.38e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—AKT1—meningioma	2.97e-05	4.34e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PTEN—meningioma	2.92e-05	4.28e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—AKT1—meningioma	2.92e-05	4.28e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—AKT1—meningioma	2.92e-05	4.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTEN—meningioma	2.91e-05	4.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—ERBB2—meningioma	2.9e-05	4.24e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—ERBB2—meningioma	2.87e-05	4.2e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PDGFB—meningioma	2.77e-05	4.05e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—PTEN—meningioma	2.76e-05	4.04e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—AKT1—meningioma	2.74e-05	4.01e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—AKT1—meningioma	2.74e-05	4.01e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—AKT1—meningioma	2.74e-05	4e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—AKT1—meningioma	2.69e-05	3.94e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—ERBB2—meningioma	2.65e-05	3.88e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—AKT1—meningioma	2.63e-05	3.84e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—ERBB2—meningioma	2.61e-05	3.82e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PTEN—meningioma	2.61e-05	3.82e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—AKT1—meningioma	2.61e-05	3.81e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—meningioma	2.58e-05	3.77e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—meningioma	2.56e-05	3.74e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—meningioma	2.55e-05	3.73e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TSHB—meningioma	2.53e-05	3.7e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—meningioma	2.52e-05	3.68e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—meningioma	2.47e-05	3.62e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—meningioma	2.45e-05	3.58e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—meningioma	2.42e-05	3.55e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—meningioma	2.42e-05	3.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—meningioma	2.39e-05	3.5e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—meningioma	2.36e-05	3.45e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—meningioma	2.33e-05	3.41e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—meningioma	2.33e-05	3.4e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—meningioma	2.28e-05	3.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—meningioma	2.27e-05	3.33e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—meningioma	2.26e-05	3.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—meningioma	2.23e-05	3.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—meningioma	2.2e-05	3.22e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—meningioma	2.19e-05	3.21e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—meningioma	2.18e-05	3.19e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—meningioma	2.18e-05	3.19e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—meningioma	2.15e-05	3.14e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—meningioma	2.15e-05	3.14e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—meningioma	2.1e-05	3.07e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—meningioma	2.07e-05	3.03e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—meningioma	2.07e-05	3.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—meningioma	2.04e-05	2.99e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—meningioma	2.03e-05	2.98e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—meningioma	2.01e-05	2.94e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—meningioma	2e-05	2.92e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—meningioma	1.99e-05	2.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—meningioma	1.99e-05	2.91e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—meningioma	1.99e-05	2.9e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—meningioma	1.94e-05	2.84e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—meningioma	1.93e-05	2.83e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—meningioma	1.92e-05	2.81e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—meningioma	1.91e-05	2.8e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—meningioma	1.86e-05	2.71e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—meningioma	1.84e-05	2.7e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—meningioma	1.83e-05	2.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—meningioma	1.83e-05	2.68e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—meningioma	1.82e-05	2.66e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—meningioma	1.79e-05	2.62e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—meningioma	1.78e-05	2.61e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—meningioma	1.77e-05	2.59e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—meningioma	1.69e-05	2.47e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—meningioma	1.69e-05	2.47e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—meningioma	1.68e-05	2.46e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—meningioma	1.59e-05	2.33e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—meningioma	1.58e-05	2.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—meningioma	1.52e-05	2.22e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—meningioma	1.51e-05	2.2e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—meningioma	1.49e-05	2.18e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—meningioma	1.48e-05	2.17e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—meningioma	1.47e-05	2.15e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—meningioma	1.47e-05	2.14e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—meningioma	1.42e-05	2.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—meningioma	1.41e-05	2.06e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—meningioma	1.41e-05	2.06e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—meningioma	1.4e-05	2.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—meningioma	1.39e-05	2.04e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—meningioma	1.31e-05	1.92e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—meningioma	1.3e-05	1.91e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—meningioma	1.28e-05	1.88e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—meningioma	1.26e-05	1.84e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—meningioma	1.24e-05	1.81e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—meningioma	1.22e-05	1.78e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—meningioma	1.19e-05	1.75e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—meningioma	1.19e-05	1.74e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—meningioma	1.18e-05	1.72e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—meningioma	1.12e-05	1.64e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—meningioma	1.08e-05	1.58e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—meningioma	1.03e-05	1.51e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—meningioma	9.12e-06	1.33e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—meningioma	8.94e-06	1.31e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—meningioma	8.55e-06	1.25e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—meningioma	8.08e-06	1.18e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—meningioma	6.9e-06	1.01e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—meningioma	6.45e-06	9.44e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—meningioma	5.15e-06	7.54e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—meningioma	3.98e-06	5.82e-06	CbGpPWpGaD
